Alpine Immune Sciences to Present at 2019 Ladenburg Thalmann Healthcare Conference
September 17 2019 - 6:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for cancer, autoimmune/inflammatory, and
other diseases, today announced the company will present at the
2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September
24, 2019 at 3:00 p.m. Eastern Time in New York, NY.
A live webcast of the presentation will be available online in
the investor relations section of the company’s website at
https://ir.alpineimmunesciences.com/events. A replay of the
presentation will be available on the company website for 90 days
following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave
of immune therapeutics, creating potentially powerful
multifunctional immunotherapies to improve patients’ lives via
unique protein engineering technologies. Alpine has two lead
programs. The first, ALPN-101 for autoimmune/inflammatory diseases,
is a selective dual T-cell costimulation blocker engineered to
reduce pathogenic T and B cell immune responses by blocking ICOS
and CD28. ALPN-101 is currently enrolling a phase I healthy
volunteer trial. The second, ALPN-202 for cancer, is a conditional
CD28 costimulator and dual checkpoint inhibitor. Alpine is backed
by world-class research and development capabilities, a
highly-productive scientific platform, and a proven management
team. For more information, visit www.alpineimmunesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005317/en/
Investor Relations: Pure Communications Courtney Dugan,
212-257-6723 cdugan@purecommunications.com
Media Relations: Pure Communications Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2024 to May 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From May 2023 to May 2024